# A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Inju
# Laboratory Mice

Cell

183, 1070-1085.e12

DOI: 10.1016/j.cell.2020.09.050

Citation Report

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends in Immunology, 2020, 41, 1100-1115. | 2.9 | 794 |
| 2 | Severe acute respiratory syndrome coronavirusâ€2 natural animal reservoirs and experimental models: systematic review. Reviews in Medical Virology, 2021, 31, e2196. | 3.9 | 24 |
| 3 | SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science, 2020, 370, 1464-1468. | 6.0 | 808 |
| 4 | Replication, pathogenicity, and transmission of SARS-CoV-2 in minks. National Science Review, 2021, 8, nwaa291. | 4.6 | 72 |
| 5 | Considerations for the use and study of exogenous surfactant in respiratory disease from COVID-19. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 51-53. | 0.2 | 0 |
| 6 | Variants in SARS-CoV-2 associated with mild or severe outcome. Evolution, Medicine and Public Health, 2021, 9, 267-275. | 1.1 | 24 |
| 10 | Possible host-adaptation of SARS-CoV-2 due to improved ACE2 receptor binding in mink. Virus Evolution, 2021, 7, veaa094. | 2.2 | 50 |
| 11 | Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis. Immune Network, 2021, 21, e1. | 1.6 | 9 |
| 12 | SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1. | 1.9 | 104 |
| 13 | Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866. | 5.8 | 73 |
| 14 | Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science, 2021, 371, 735-741. | 6.0 | 305 |
| 16 | Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829. | 6.0 | 285 |
| 17 | Early humoral defence: Contributing to confining COVIDâ€19 to conducting airways?. Scandinavian Journal of Immunology, 2021, 93, e13024. | 1.3 | 10 |
| 18 | SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study. Viruses, 2021, 13, 494. | 1.5 | 63 |
| 19 | Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response. Pathogens, 2021, 10, 275. | 1.2 | 3 |
| 20 | Animal Hosts and Experimental Models of SARS-CoV-2 Infection. Chemotherapy, 2021, 66, 1-9. | 0.8 | 13 |
| 21 | Vaccines: Underlying Principles of Design and Testing. Clinical Pharmacology and Therapeutics, 2021, 109, 987-999. | 2.3 | 2 |
| 26 | Mechanisms of SARSâ€CoVâ€2â€induced lung vascular disease: potential role of complement. Pulmonary Circulation, 2021, 11, 1-14. | 0.8 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 29 | The variant gambit: COVID-19â€™s next move. Cell Host and Microbe, 2021, 29, 508-515. | 5.1 | 305 |
| 30 | Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. MBio, 2021, 12, . | 1.8 | 8 |
| 31 | COVID19 therapeutics: Expanding the antiviral arsenal. EBioMedicine, 2021, 66, 103289. | 2.7 | 4 |
| 33 | Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. EBioMedicine, 2021, 66, 103291. | 2.7 | 15 |
| 34 | Intranasal versus intratracheal exposure to lipopolysaccharides in a murine model of acute respiratory distress syndrome. Scientific Reports, 2021, 11, 7777. | 1.6 | 22 |
| 35 | Current Status of Putative Animal Sources of SARS-CoV-2 Infection in Humans: Wildlife, Domestic Animals and Pets. Microorganisms, 2021, 9, 868. | 1.6 | 38 |
| 36 | Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell, 2021, 184, 1804-1820.e16. | 13.5 | 297 |
| 37 | The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathologica, 2021, 141, 809-822. | 3.9 | 94 |
| 39 | Convergent evolution of SARS-CoV-2 in human and animals. Protein and Cell, 2021, 12, 832-835. | 4.8 | 15 |
| 42 | Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nature Reviews Microbiology, 2021, 19, 425-441. | 13.6 | 202 |
| 43 | Cell-Type Apoptosis in Lung during SARS-CoV-2 Infection. Pathogens, 2021, 10, 509. | 1.2 | 47 |
| 45 | SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell, 2021, 184, 2605-2617.e18. | 13.5 | 151 |
| 46 | Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science, 2021, 372, 1108-1112. | 6.0 | 210 |
| 48 | SARS-CoV-2 Rapidly Adapts in Aged BALB/c Mice and Induces Typical Pneumonia. Journal of Virology, 2021, 95, . | 1.5 | 43 |
| 49 | Q493K and Q498H substitutions in Spike promote adaptation of SARS-CoV-2 in mice. EBioMedicine, 2021, 67, 103381. | 2.7 | 102 |
| 51 | Noninvasive Measurement of Pulmonary Function in Experimental Mouse Models of Airway Disease. Lung, 2021, 199, 255-261. | 1.4 | 13 |
| 53 | Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine, 2021, 2, 100313. | 3.3 | 56 |
| 55 | Platforms for Personalized Polytherapeutics Discovery in COVID-19. Journal of Molecular Biology, 2021, 433, 166945. | 2.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 57 | Psychosocial Risk Factors, Noncommunicable Diseases, and Animal Models for COVID-19. Biological Psychiatry, 2021, 89, e67-e71. | 0.7 | 1 |
| 58 | COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160. | 1.8 | 26 |
| 59 | Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?. Journal of Antimicrobial Chemotherapy, 2021, 76, 2230-2233. | 1.3 | 17 |
| 60 | Exploration of the Function of Ginsenoside RD Attenuates Lipopolysaccharide-Induced Lung Injury: A Study of Network Pharmacology and Experimental Validation. Shock, 2022, 57, 212-220. | 1.0 | 6 |
| 62 | SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nature Communications, 2021, 12, 3587. | 5.8 | 71 |
| 63 | Control of Innate Immune Activation by Severe Acute Respiratory Syndrome Coronavirus 2 and Other Coronaviruses. Journal of Interferon and Cytokine Research, 2021, 41, 205-219. | 0.5 | 5 |
| 64 | Animal models for SARS-CoV-2. Current Opinion in Virology, 2021, 48, 73-81. | 2.6 | 52 |
| 65 | Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. Cells, 2021, 10, 1412. | 1.8 | 6 |
| 66 | Aging and respiratory viral infection: from acute morbidity to chronic sequelae. Cell and Bioscience, 2021, 11, 112. | 2.1 | 20 |
| 68 | Reinvestigating the Coughing Rat Model of Pertussis To Understand Bordetella pertussis Pathogenesis. Infection and Immunity, 2021, 89, e0030421. | 1.0 | 8 |
| 69 | Quantitative proteomics of hamster lung tissues infected with SARSâ€CoVâ€2 reveal host factors having implication in the disease pathogenesis and severity. FASEB Journal, 2021, 35, e21713. | 0.2 | 22 |
| 71 | Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. International Journal of Molecular Sciences, 2021, 22, 7425. | 1.8 | 69 |
| 73 | On the origin of SARS-CoV-2â€”The blind watchmaker argument. Science China Life Sciences, 2021, 64, 1560-1563. | 2.3 | 18 |
| 74 | Sex and age bias viral burden and interferon responses during SARS-CoV-2 infection in ferrets. Scientific Reports, 2021, 11, 14536. | 1.6 | 14 |
| 75 | ACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions. PLoS Pathogens, 2021, 17, e1009723. | 2.1 | 28 |
| 76 | Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host and Microbe, 2021, 29, 1052-1062. | 5.1 | 185 |
| 77 | Toward Understanding COVID-19 Recovery: National Institutes of Health Workshop on Postacute COVID-19. Annals of Internal Medicine, 2021, 174, 999-1003. | 2.0 | 65 |
| 78 | Expression of the ACE2 Virus Entry Protein in the Nervus Terminalis Reveals the Potential for an Alternative Route to Brain Infection in COVID-19. Frontiers in Cellular Neuroscience, 2021, 15, 674123. | 1.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 80 | Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Reports, 2021, 36, 109450. | 2.9 | 38 |
| 84 | InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32. | 13.5 | 228 |
| 85 | COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6. | 6.6 | 59 |
| 86 | Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model. MBio, 2021, 12, e0097421. | 1.8 | 69 |
| 88 | Neurochemical biomarkers to study CNS effects of COVIDâ€19: A narrative review and synthesis. Journal of Neurochemistry, 2021, 159, 61-77. | 2.1 | 21 |
| 89 | Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. Thorax, 2022, 77, 203-209. | 2.7 | 90 |
| 90 | An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens, 2021, 10, 1030. | 1.2 | 33 |
| 92 | Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science, 2021, 373, 991-998. | 6.0 | 144 |
| 94 | Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. Frontiers in Microbiology, 2021, 12, 626553. | 1.5 | 90 |
| 95 | Long-Term Acute Care Hospital Outcomes of Mechanically Ventilated Patients With Coronavirus Disease 2019*. Critical Care Medicine, 2022, 50, 256-263. | 0.4 | 13 |
| 96 | Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature, 2021, 599, 465-470. | 13.7 | 129 |
| 97 | Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Reports, 2021, 36, 109760. | 2.9 | 80 |
| 98 | Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus. Journal of Thrombosis and Haemostasis, 2021, 19, 2652-2658. | 1.9 | 29 |
| 99 | Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 2021, 54, 2143-2158.e15. | 6.6 | 155 |
| 102 | A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Science Advances, 2021, 7, eabh1547. | 4.7 | 44 |
| 103 | Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. Nature Communications, 2021, 12, 5654. | 5.8 | 89 |
| 104 | The viral phoenix: enhanced infectivity and immunity evasion of SARS-CoV-2 variants. Environmental Chemistry Letters, 2022, 20, 1539-1544. | 8.3 | 6 |
| 105 | SARS-CoV-2 Subgenomic RNAs: Characterization, Utility, and Perspectives. Viruses, 2021, 13, 1923. | 1.5 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 107 | Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421. | 1.5 | 12 |
| 108 | Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. PLoS Pathogens, 2021, 17, e1009897. | 2.1 | 49 |
| 111 | The origins of SARS-CoV-2: A critical review. Cell, 2021, 184, 4848-4856. | 13.5 | 330 |
| 113 | COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines, 2021, 9, 1082. | 2.1 | 8 |
| 115 | Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19. Journal of Virology, 2021, 95, e0101021. | 1.5 | 21 |
| 116 | Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity. Lancet Infectious Diseases, The, 2021, 21, e296-e301. | 4.6 | 57 |
| 117 | Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16. | 13.5 | 131 |
| 118 | SARS-CoV-2, COVID-19 and the aging immune system. Nature Aging, 2021, 1, 769-782. | 5.3 | 208 |
| 119 | Potential Therapeutic Applications of Pulmonary Surfactant Lipids in the Host Defence Against Respiratory Viral Infections. Frontiers in Immunology, 2021, 12, 730022. | 2.2 | 16 |
| 120 | COVID-19â€“Associated Acute Respiratory Distress Syndrome. Critical Care Clinics, 2021, 37, 777-793. | 1.0 | 6 |
| 121 | Adenovirus transduction to express human ACE2 causes obesity-specific morbidity in mice, impeding studies on the effect of host nutritional status on SARS-CoV-2 pathogenesis. Virology, 2021, 563, 98-106. | 1.1 | 6 |
| 122 | Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931. | | 18 |
| 134 | Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. Journal of Clinical Investigation, 2020, 130, 6204-6213. | 3.9 | 59 |
| 135 | Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97. | 1.1 | 12 |
| 136 | Mouse Models for the Study of SARS-CoV-2 Infection. Comparative Medicine, 2021, 71, 383-397. | 0.4 | 11 |
| 137 | Cross-protective immunity following coronavirus vaccination and coronavirus infection. Journal of Clinical Investigation, 2021, 131, . | 3.9 | 51 |
| 138 | Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929. | 2.9 | 64 |
| 139 | SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. Journal of Virology, 2022, 96, JVI0151121. | 1.5 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 140 | Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine, 2021, 73, 103643. | 2.7 | 127 |
| 141 | Distinct Roles of Type I and Type III Interferons during a Native Murine Î² Coronavirus Lung Infection. Journal of Virology, 2022, 96, JVI0124121. | 1.5 | 10 |
| 142 | Update on and Future Directions for Use of Antiâ€“SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Annals of Internal Medicine, 2022, 175, 119-126. | 2.0 | 13 |
| 143 | Male Sex and Age Biases Viral Burden, Viral Shedding, and Type 1 and 2 Interferon Responses During SARS-CoV-2 Infection in Ferrets. SSRN Electronic Journal, 0, , . | 0.4 | 1 |
| 144 | The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Journal of Virology, 2022, 96, JVI0096421. | 1.5 | 84 |
| 145 | An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19. Science, 2021, 374, 1586-1593. | 6.0 | 1,074 |
| 146 | Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biology, 2021, 19, e3001284. | 2.6 | 54 |
| 147 | Using in vivo animal models for studying SARS-CoV-2. Expert Opinion on Drug Discovery, 2022, 17, 121-137. | 2.5 | 5 |
| 148 | Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption. PLoS Pathogens, 2021, 17, e1010053. | 2.1 | 43 |
| 149 | A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125. | 5.8 | 93 |
| 150 | Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. Translational Research, 2022, 240, 1-16. | 2.2 | 33 |
| 152 | Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2. Cell Discovery, 2021, 7, 74. | 3.1 | 1 |
| 153 | Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses â€" are we our own worst enemy?. Nature Reviews Immunology, 2022, 22, 47-56. | 10.6 | 118 |
| 155 | Animal models for SARSâ€CoVâ€2 infection and pathology. MedComm, 2021, 2, 548-568. | 3.1 | 19 |
| 157 | Neurological complications and infection mechanism of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2021, 6, 406. | 7.1 | 76 |
| 158 | Treatment with Fluticasone Propionate Increases Antibiotic Efficacy during Treatment of Late-Stage Primary Pneumonic Plague. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0127521. | 1.4 | 2 |
| 160 | â€œBut Mouse, You Are Not Aloneâ€: On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting Mice. ILAR Journal, 2021, 62, 48-59. | 1.8 | 10 |
| 161 | Immune responses to human respiratory coronaviruses infection in mouse models. Current Opinion in Virology, 2022, 52, 102-111. | 2.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 162 | Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2. Cell Discovery, 2021, 7, 74. | 3.1 | 10 |
| 163 | Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature, 2022, 603, 587-598. | 13.7 | 216 |
| 164 | Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat modelÂthat mimics moderate and severe Covidâ€19 pathology. Clinical and Experimental Pharmacology and Physiology, 2022, 49, 483-491. | 0.9 | 18 |
| 167 | Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19. Scientific Reports, 2022, 12, 1299. | 1.6 | 15 |
| 168 | A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. Science Advances, 2022, 8, eabh3827. | 4.7 | 27 |
| 169 | Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2022, 7, . | 5.6 | 61 |
| 170 | SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692. | 13.7 | 475 |
| 171 | ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNÎ³-driven immunopathology. ELife, 2022, 11, . | 2.8 | 42 |
| 172 | COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment â€“ Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227. | 1.9 | 19 |
| 173 | Type I interferons and SARS-CoV-2: from cells to organisms. Current Opinion in Immunology, 2022, 74, 172-182. | 2.4 | 49 |
| 174 | ExÂvivo and inÂvivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. Molecular Therapy, 2022, 30, 2005-2023. | 3.7 | 10 |
| 175 | Animal models for SARS-CoV-2 and SARS-CoV-1 pathogenesis, transmission and therapeutic evaluation. World Journal of Virology, 2022, 11, 40-56. | 1.3 | 9 |
| 176 | SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response. Nature Aging, 2022, 2, 115-124. | 5.3 | 43 |
| 177 | SARSâ€CoVâ€2 Omicron emergence urges for reinforced Oneâ€Health surveillance. EMBO Molecular Medicine, 2022, , e15558. | 3.3 | 10 |
| 178 | Advances and gaps in SARS-CoV-2 infection models. PLoS Pathogens, 2022, 18, e1010161. | 2.1 | 61 |
| 179 | The Tissue Distribution of SARS-CoV-2 in Transgenic Mice With Inducible Ubiquitous Expression of hACE2. Frontiers in Molecular Biosciences, 2021, 8, 821506. | 1.6 | 7 |
| 180 | An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, . | 5.8 | 57 |
| 183 | Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. Frontiers in Immunology, 2022, 13, 821664. | 2.2 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 184 | An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell, 2022, 185, 614-629.e21. | 13.5 | 40 |
| 185 | Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, 2022, 185, 896-915.e19. | 13.5 | 189 |
| 186 | Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?. Antibiotics, 2022, 11, 220. | 1.5 | 66 |
| 187 | Qingwenzhike Prescription Alleviates Acute Lung Injury Induced by LPS via Inhibiting TLR4/NF-kB Pathway and NLRP3 Inflammasome Activation. Frontiers in Pharmacology, 2021, 12, 790072. | 1.6 | 32 |
| 188 | Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. Journal of Genetics and Genomics, 2021, 48, 1111-1121. | 1.7 | 206 |
| 189 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , . | 13.7 | 101 |
| 190 | Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670. | 13.7 | 917 |
| 195 | Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science, 2022, 375, 864-868. | 6.0 | 394 |
| 197 | An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305. | 5.8 | 4 |
| 198 | Administration of aerosolized SARS-CoV-2 to K18-hACE2 mice uncouples respiratory infection from fatal neuroinvasion. Science Immunology, 2021, , eabl9929. | 5.6 | 3 |
| 199 | Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy, 2021, 6, 420. | 7.1 | 46 |
| 204 | Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression. Viruses, 2022, 14, 535. | 1.5 | 47 |
| 205 | Porcine Respiratory Coronavirus as a Model for Acute Respiratory Coronavirus Disease. Frontiers in Immunology, 2022, 13, 867707. | 2.2 | 11 |
| 206 | Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. Medical Microbiology and Immunology, 2022, 211, 79-103. | 2.6 | 9 |
| 208 | Comparative characterization of SARSâ€CoVâ€2 variants of concern and mouseâ€adapted strains in mice. Journal of Medical Virology, 2022, 94, 3223-3232. | 2.5 | 12 |
| 209 | Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19. Nature, 2022, 605, 146-151. | 13.7 | 82 |
| 210 | Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. Scientific Reports, 2022, 12, 4150. | 1.6 | 9 |
| 212 | Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2. PLoS Pathogens, 2022, 18, e1010093. | 2.1 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 213 | Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion. MBio, 2022, 13, e0009922. | 1.8 | 22 |
| 214 | Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. ELife, 2022, 11, . | 2.8 | 37 |
| 215 | Spatial Transcriptome Uncovers the Mouse Lung Architectures and Functions. Frontiers in Genetics, 2022, 13, 858808. | 1.1 | 3 |
| 216 | SARS-CoV-2 infection of airway cells causes intense viral and cell shedding, two spreading mechanisms affected by IL-13. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119680119. | 3.3 | 53 |
| 217 | Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Science Translational Medicine, 2022, 14, eabm3410. | 5.8 | 49 |
| 218 | A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226. | 5.6 | 22 |
| 219 | Interstitial pneumonia and diffuse alveolar damage in domestic animals. Veterinary Pathology, 2022, 59, 586-601. | 0.8 | 6 |
| 220 | SARS-CoV-2 pathogenesis. Nature Reviews Microbiology, 2022, 20, 270-284. | 13.6 | 404 |
| 221 | Review of selected animal models for respiratory coronavirus infection and its application in drug research. Journal of Medical Virology, 2022, , . | 2.5 | 5 |
| 222 | Mutations of Omicron Variant at the Interface of the Receptor Domain Motif and Human Angiotensin-Converting Enzyme-2. International Journal of Molecular Sciences, 2022, 23, 2870. | 1.8 | 18 |
| 223 | Animal models in SARS-CoV-2 research. Nature Methods, 2022, 19, 392-394. | 9.0 | 51 |
| 226 | mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. Vaccines, 2021, 9, 1503. | 2.1 | 23 |
| 227 | SARS-CoV-2 Variants of Concern Infect the Respiratory Tract and Induce Inflammatory Response in Wild-Type Laboratory Mice. Viruses, 2022, 14, 27. | 1.5 | 21 |
| 228 | Modeling of experimental acute bronchopneumonia with pulmonary fibrosis. Experimental and Clinical Physiology and Biochemistry, 2022, 2021, . | 0.2 | 0 |
| 229 | Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice. Signal Transduction and Targeted Therapy, 2021, 6, 439. | 7.1 | 18 |
| 232 | Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients. Frontiers in Aging, 2021, 2, . | 1.2 | 12 |
| 233 | An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine, 2022, 14, eabn6859. | 5.8 | 31 |
| 236 | Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model. EBioMedicine, 2022, 79, 103999. | 2.7 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 237 | SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. Inflammation, 2022, 45, 1430-1449. | 1.7 | 16 |
| 238 | Animal models for studying COVID-19, prevention, and therapy: Pathology and disease phenotypes. Veterinary Pathology, 2022, 59, 516-527. | 0.8 | 5 |
| 239 | Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice. Frontiers in Immunology, 2022, 13, 819058. | 2.2 | 1 |
| 241 | Potential for a Plant-Made SARS-CoV-2 Neutralizing Monoclonal Antibody as a Synergetic Cocktail Component. Vaccines, 2022, 10, 772. | 2.1 | 10 |
| 243 | Immunity to enteric viruses. Immunity, 2022, 55, 800-818. | 6.6 | 20 |
| 244 | <scp>PF</scp>â€07321332 (Nirmatrelvir) does not interact with human <scp>ENT1</scp> or <scp>ENT2</scp>: Implications for <scp>COVID</scp>â€19 patients. Clinical and Translational Science, 2022, 15, 1599-1605. | 1.5 | 12 |
| 245 | A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2. Nature Metabolism, 2022, 4, 547-558. | 5.1 | 14 |
| 246 | Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components. Frontiers in Immunology, 2022, 13, 842453. | 2.2 | 4 |
| 248 | COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146. | 7.1 | 153 |
| 249 | Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Frontiers in Microbiology, 2022, 13, . | 1.5 | 39 |
| 250 | Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature, 2022, 607, 119-127. | 13.7 | 174 |
| 251 | Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming. Cellular and Molecular Life Sciences, 2022, 79, 301. | 2.4 | 9 |
| 252 | Caspase-4/11 exacerbates disease severity in SARSâ€“CoV-2 infection by promoting inflammation and immunothrombosis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2202012119. | 3.3 | 25 |
| 255 | Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. Npj Vaccines, 2022, 7, . | 2.9 | 8 |
| 256 | Immune-Mediated Mechanisms of COVID-19 Neuropathology. Frontiers in Neurology, 2022, 13, . | 1.1 | 9 |
| 257 | Structural and biochemical mechanism for increased infectivity and immune evasion of OmicronÂBA.2 variant compared to BA.1 and their possible mouse origins. Cell Research, 2022, 32, 609-620. | 5.7 | 63 |
| 258 | Up or down: where comes Omicron?. Cell Research, 2022, 32, 601-602. | 5.7 | 5 |
| 259 | Differential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice. Viruses, 2022, 14, 1139. | 1.5 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 260 | Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. Microbiology Spectrum, 2022, 10, . | 1.2 | 24 |
| 262 | Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070. | 2.0 | 1 |
| 264 | Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970. | 7.0 | 39 |
| 267 | SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 268 | Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. Vaccines, 2022, 10, 944. | 2.1 | 5 |
| 269 | Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein. Critical Care, 2022, 26, . | 2.5 | 8 |
| 271 | Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, . | 2.2 | 10 |
| 272 | Animal Models for COVID-19 Therapeutic Development: Where We Are and Where We Need to Go. Frontiers in Microbiology, 0, 13, . | 1.5 | 7 |
| 273 | The nervous system during <scp>COVID</scp>â€19: Caught in the crossfire. Immunological Reviews, 2022, 311, 90-111. | 2.8 | 9 |
| 274 | LncRNA MALAT1 Participates in Protection of High-Molecular-Weight Hyaluronan against Smoke-Induced Acute Lung Injury by Upregulation of SOCS-1. Molecules, 2022, 27, 4128. | 1.7 | 2 |
| 275 | Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. Cell and Bioscience, 2022, 12, . | 2.1 | 7 |
| 276 | Cell and Animal Models for SARS-CoV-2 Research. Viruses, 2022, 14, 1507. | 1.5 | 9 |
| 277 | Animal models for COVID-19: advances, gaps and perspectives. Signal Transduction and Targeted Therapy, 2022, 7, . | 7.1 | 40 |
| 278 | A Multitrait Locus Regulates Sarbecovirus Pathogenesis. MBio, 2022, 13, . | 1.8 | 11 |
| 279 | Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nature Communications, 2022, 13, . | 5.8 | 19 |
| 280 | Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Science Advances, 2022, 8, . | 4.7 | 27 |
| 281 | SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, . | 5.8 | 55 |
| 283 | Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection. Nature Genetics, 2022, 54, 1078-1089. | 9.4 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 284 | A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine. MBio, 2022, 13, . | 1.8 | 17 |
| 285 | Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron. Cell Research, 2022, 32, 831-842. | 5.7 | 16 |
| 286 | Evolution of ACE2-independent SARS-CoV-2 infection and mouse adaption after passage in cells expressing human and mouse ACE2. Virus Evolution, 2022, 8, . | 2.2 | 14 |
| 287 | SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 28 |
| 288 | Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants. Journal of Virology, 2022, 96, . | 1.5 | 12 |
| 289 | Structural bases for the higher adherence to ACE2 conferred by the SARS-CoV-2 spike Q498Y substitution. Acta Crystallographica Section D: Structural Biology, 2022, 78, 1156-1170. | 1.1 | 2 |
| 290 | Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling. Journal of Virology, 2022, 96, . | 1.5 | 7 |
| 291 | PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Communications Biology, 2022, 5, . | 2.0 | 7 |
| 292 | Tracing the origin of Severe acute respiratory syndrome Coronavirusâ€‚ (SARSâ€CoVâ€‚): A systematic review and narrative synthesis. Journal of Medical Virology, 0, , . | 2.5 | 3 |
| 293 | Cellular Imaging Analysis Algorithm-Based Assessment and Prediction of Disease in Patients with Acute Lung Injury. Contrast Media and Molecular Imaging, 2022, 2022, 1-11. | 0.4 | 1 |
| 294 | Understanding COVID-19-associated coagulopathy. Nature Reviews Immunology, 2022, 22, 639-649. | 10.6 | 137 |
| 295 | COVID-19: A Veterinary and One Health Perspective. Journal of the Indian Institute of Science, 2022, 102, 689-709. | 0.9 | 2 |
| 298 | SARSâ€CoVâ€‚ does not infect pigs, but this has to be verified regularly. Xenotransplantation, 2022, 29, . | 1.6 | 3 |
| 299 | Common human genetic variants of APOE impact murine COVID-19 mortality. Nature, 2022, 611, 346-351. | 13.7 | 29 |
| 300 | Impaired immune response drives age-dependent severity of COVID-19. Journal of Experimental Medicine, 2022, 219, . | 4.2 | 26 |
| 301 | Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice. Cell Reports, 2022, 40, 111359. | 2.9 | 23 |
| 302 | Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. PLoS Pathogens, 2022, 18, e1010867. | 2.1 | 17 |
| 303 | ZBTB7A promotes virus-host homeostasis during human coronavirus 229E infection. Cell Reports, 2022, 41, 111540. | 2.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 304 | Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex. Npj Vaccines, 2022, 7, . | 2.9 | 2 |
| 305 | TLR7 controls myeloid-derived suppressor cells expansion and function in the lung of C57BL6 mice infected with Schistosoma japonicum. PLoS Neglected Tropical Diseases, 2022, 16, e0010851. | 1.3 | 0 |
| 306 | COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics. Drug Metabolism and Disposition, 2023, 51, 130-141. | 1.7 | 11 |
| 307 | Early pathogenesis profiles across SARS-CoV-2 variants in K18-hACE2 mice revealed differential triggers of lung damages. Frontiers in Immunology, 0, 13, . | 2.2 | 1 |
| 308 | Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. Nature Communications, 2022, 13, . | 5.8 | 31 |
| 310 | Structural basis for mouse receptor recognition by SARS-CoV-2 omicron variant. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 26 |
| 311 | LRRC15 inhibits SARS-CoV-2 cellular entry in trans. PLoS Biology, 2022, 20, e3001805. | 2.6 | 10 |
| 312 | Characteristics of animal models for COVIDâ€19. Animal Models and Experimental Medicine, 2022, 5, 401-409. | 1.3 | 7 |
| 313 | Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 15 |
| 314 | Anti-SARS-CoV-2 Activity of Adamantanes In Vitro and in Animal Models of Infection. Covid, 2022, 2, 1551-1563. | 0.7 | 2 |
| 315 | Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection. Journal of Pharmaceutical Analysis, 2023, 13, 255-261. | 2.4 | 7 |
| 316 | Anti-inflammatory potential of turmeric, amla, and black pepper mixture against sepsis-induced acute lung injury in rats. Journal of Food Science and Technology, 2023, 60, 252-261. | 1.4 | 1 |
| 317 | SARS-CoV-2 infection of sustentacular cells disrupts olfactory signaling pathways. JCI Insight, 2022, 7, . | 2.3 | 16 |
| 318 | A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains. Frontiers in Immunology, 0, 13, . | 2.2 | 3 |
| 320 | Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. EBioMedicine, 2022, 86, 104341. | 2.7 | 20 |
| 321 | Glycyrrhiza uralensis polysaccharides ameliorate acute lung injury by inhibiting the activation of multiple inflammasomes. Journal of Functional Foods, 2023, 100, 105386. | 1.6 | 3 |
| 322 | Phenothiazines inhibit SARS-CoV-2 cell entry via a blockade of spike protein binding to neuropilin-1. Antiviral Research, 2023, 209, 105481. | 1.9 | 13 |
| 323 | Immunosenescence and inflamm-ageing in COVID-19. Ageing Research Reviews, 2023, 84, 101818. | 5.0 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-Î² signaling. Nature Communications, 2022, 13, . | 5.8 | 18 |
| 326 | Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. IScience, 2022, 25, 105701. | 1.9 | 1 |
| 328 | Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice. Scientific Reports, 2022, 12, . | 1.6 | 2 |
| 329 | Animal Models to Test SARS-CoV-2 Vaccines: Which Ones Are in Use and Future Expectations. Pathogens, 2023, 12, 20. | 1.2 | 4 |
| 331 | Upregulation of Robo4 expression by SMAD signaling suppresses vascular permeability and mortality in endotoxemia and COVID-19 models. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 4 |
| 333 | Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. Trends in Microbiology, 2023, 31, 644-656. | 3.5 | 7 |
| 334 | A C57BL/6 Mouse Model of SARS-CoV-2 Infection Recapitulates Age- and Sex-Based Differences in Human COVID-19 Disease and Recovery. Vaccines, 2023, 11, 47. | 2.1 | 6 |
| 335 | Mouse Adapted SARS-CoV-2 (MA10) Viral Infection Induces Neuroinflammation in Standard Laboratory Mice. Viruses, 2023, 15, 114. | 1.5 | 7 |
| 337 | Animal models of COVID-19 and complications. , 2023, , 623-636. | | 0 |
| 340 | Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant. Microorganisms, 2023, 11, 431. | 1.6 | 1 |
| 341 | Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 3 |
| 342 | Does viral inoculum play a role in disease severity in COVIDâ€19?. Journal of Medical Virology, 2023, 95, . | 2.5 | 0 |
| 343 | Respiratory viruses: New frontiersâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2023, 1522, 60-73. | 1.8 | 0 |
| 344 | Mouse-Adapted SARS-CoV-2 MA10 Strain Displays Differential Pulmonary Tropism and Accelerated Viral Replication, Neurodissemination, and Pulmonary Host Responses in K18-hACE2 Mice. MSphere, 2023, 8, . | 1.3 | 3 |
| 345 | Cell-autonomous requirement for ACE2 across organs in lethal mouse SARS-CoV-2 infection. PLoS Biology, 2023, 21, e3001989. | 2.6 | 6 |
| 346 | Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. Npj Vaccines, 2023, 8, . | 2.9 | 3 |
| 347 | Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity, 2023, 56, 669-686.e7. | 6.6 | 43 |
| 348 | Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. PLoS Pathogens, 2023, 19, e1011168. | 2.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 349 | Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19. Science Immunology, 2023, 8, . | 5.6 | 7 |
| 350 | SARSâ€CoVâ€2â€related bat virus behavior in humanâ€relevant models sheds light on the origin of COVIDâ€19. EMBO Reports, 2023, 24, . | 2.0 | 4 |
| 351 | Interferonâ€induced transmembrane protein 3 (IFITM3) limits lethality of SARSâ€CoVâ€2 in mice. EMBO Reports, 2023, 24, . | 2.0 | 13 |
| 352 | Prime-Pull Immunization of Mice with a BcfA-Adjuvanted Vaccine Elicits Sustained Mucosal Immunity That Prevents SARS-CoV-2 Infection and Pathology. Journal of Immunology, 2023, 210, 1257-1271. | 0.4 | 5 |
| 353 | Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 9 |
| 354 | A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses. MBio, 2023, 14, . | 1.8 | 3 |
| 355 | A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses. MSphere, 2023, 8, . | 1.3 | 0 |
| 356 | A Critical Analysis of the Evidence for the SARS-CoV-2 Origin Hypotheses. Journal of Virology, 2023, 97, . | 1.5 | 9 |
| 357 | SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. Antiviral Research, 2023, 212, 105580. | 1.9 | 2 |
| 359 | Recombinant measles virus expressing prefusion spike protein stabilized by six rather than two prolines is more efficacious against SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2023, 95, . | 2.5 | 1 |
| 360 | Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models. PLoS Pathogens, 2023, 19, e1011240. | 2.1 | 6 |
| 362 | Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Reports, 2023, 42, 112326. | 2.9 | 13 |
| 363 | Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant. MBio, 2023, 14, . | 1.8 | 9 |
| 364 | Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, . | 3.3 | 15 |
| 365 | 1-O-Octadecyl-2-O-benzyl-sn-glyceryl-3-phospho-GS-441524 (V2043). Evaluation of Oral V2043 in a Mouse Model of SARS-CoV-2 Infection and Synthesis and Antiviral Evaluation of Additional Phospholipid Esters with Enhanced Anti-SARS-CoV-2 Activity. Journal of Medicinal Chemistry, 2023, 66, 5802-5819. | 2.9 | 3 |
| 399 | Animal models to study the neurological manifestations of the post-COVID-19 condition. Lab Animal, 2023, 52, 202-210. | 0.2 | 2 |
| 451 | Pathogenesis of viral infection. , 2024, , 2187-2207. | | 0 |
| 467 | Histopathology assay of the lung after intratracheal injection of SARS-CoV-2 spike protein recombinant in mice: A preliminary study. AIP Conference Proceedings, 2024, , . | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|